Entity Details
| Primary name |
TRPM6_HUMAN |
| Entity type |
UniProt |
| Source |
Source Link |
Details
| Accession | Q9BX84 |
| EntryName | TRPM6_HUMAN |
| FullName | Transient receptor potential cation channel subfamily M member 6 |
| TaxID | 9606 |
| Evidence | evidence at protein level |
| Length | 2022 |
| SequenceStatus | complete |
| DateCreated | 2004-12-07 |
| DateModified | 2021-06-02 |
Subcellular Location
Show/Hide Table
| Subcellular Location |
| Cell membrane |
Domains
Show/Hide Table
| Domain | Name | Category | Type |
| IPR004166 | MHCK/EF2 kinase | Domain | Domain |
| IPR005821 | Ion transport domain | Domain | Domain |
| IPR011009 | Protein kinase-like domain superfamily | Family | Homologous superfamily |
| IPR029597 | Transient receptor potential cation channel subfamily M member 6 | Family | Family |
| IPR032415 | TRPM, tetramerisation domain | Domain | Domain |
| IPR037162 | TRPM, tetramerisation domain superfamily | Family | Homologous superfamily |
| IPR041491 | TRPM, SLOG domain | Domain | Domain |
Diseases
Show/Hide Table
| Disease ID | Source | Name | Description |
| 602014 | OMIM | Hypomagnesemia 1 (HOMG1) | A disorder due to a primary defect in intestinal magnesium absorption. It is characterized by low levels of serum magnesium alongside with a normal renal magnesium secretion, secondary hypocalcemia and calcinocis. Affected individuals show neurologic symptoms of hypomagnesemic hypocalcemia, including seizures and muscle spasms, during infancy. Hypocalcemia is secondary to parathyroid failure resulting from magnesium deficiency. Untreated, the disorder may be fatal or may result in neurological damage. The disease is caused by variants affecting the gene represented in this entry. |
Drugs
Show/Hide Table
| Drug | Name | Source | Type |
| DB09481 | Magnesium carbonate | Drugbank | small molecule |
| DB14513 | Magnesium | Swissprot | small molecule |
Interactions
4 interactions